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Abstract Sarcomeres are the smallest contractile units of
heart and skeletal muscles and are essential for generation
and propagation of mechanical force in these striated mus-
cles. During the last decades it has become increasingly clear
that components of sarcomeres also play a fundamental role
in signal transduction in physiological and pathophysiolog-
ical conditions. Mutations or misexpression of both
sarcomeric contractile and non-contractile proteins have
been associated with a variety of cardiac diseases.
Moreover, re-expression of foetal sarcomeric proteins or
isoforms during cardiac disease can be observed,
emphasising the importance of understanding signalling in
sarcomeres in both development and disease. The prospec-
tive of pharmacological intervention at the level of the sar-
comere is now emerging and may lead to novel therapeutic
strategies for the treatment of cardiac and skeletal muscle
diseases. These aspects will be discussed in this brief review
and recent findings, which led to novel insights into the role
of the sarcomeric cytoskeleton in muscle development and
disease, will be highlighted.
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Cardiac and skeletal muscle cells share the presence of
myofibrils, highly organised cytoskeletal structures, which
are responsible for contractile activity. These myofibrils are
composed of repeating contractile units, called sarcomeres.
The uniformly arranged thin and thick myofilaments of the
sarcomeres give muscle cells their characteristic, microscop-
ically visible, striated pattern. The structure and molecular
organisation of sarcomeres are highly conserved between
species and show many similarities between cardiac and
skeletal muscle cells, despite their distinct functional differ-
ences. Henceforth, we will discuss cardiac sarcomeric orga-
nisation and function, unless otherwise stated.
Myofibrillogenesis
Studies in developing embryos have made a significant
contribution to our current knowledge of myofibril assembly
and the importance of different components of the sarco-
mere, providing us with a molecular basis for a better com-
prehension of cardiac diseases. The highly orchestrated mor-
phological and molecular events during early cardiac devel-
opment have been the subject of research in different animal
models, such as chick and mouse embryos [1]. After gastru-
lation during embryonic development, cardiogenic cells
from anterior lateral plate mesoderm can be distinguished
in the so-called cardiac crescent (first heart field). Later,
these cardiogenic cells migrate towards the ventral midline
to form the primitive linear heart tube, giving rise to the
definitive left ventricle and inflow tract. Cardiogenic cells
located medially to the cardiac crescent (second heart field)
are recruited during heart tube elongation and looping stages,
giving rise to the right ventricle and outflow tract myocardi-
um. Before fusion of cardiogenic cells to the linear heart tube
is completed, contractile sarcomeric proteins such as α-
actinin are expressed. Alpha-actinin is a major component
of the sarcomere and localised at the Z-disc, a structure that
defines the boundaries of each sarcomeric unit and thus
shared by neighbouring sarcomeres.
Besides the Z-disc, other components of the sarcomere
can be distinguished: the I-band (isotropic) surrounds the Z-
disc and is composed of only actin filaments, the A-band
(anisotropic) is composed of actin and myosin filaments and
the M-band (middle) forms the centre of each sarcomere.
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Contraction is regulated by the coordinated action of the
actin-containing thin filaments and the myosin-containing
thick filaments, which slide over each other in an ATP-
dependent manner. In the heart the giant protein titin is the
structural backbone of the sarcomere, indicated by the span-
ning of the entire Z-disc by two molecules of titin. Titin
determines the stiffness of the sarcomere, retains the A-
band in the middle of the sarcomere during contraction and
is connected with α-actinin at the Z-disc. Alpha-actinin, in
its turn, forms homodimers in an antiparallel manner and
cross-links actin.
Mutations in sarcomeric proteins are associated
with cardiomyopathies
Cardiomyopathy is a group of disorders of the heart that result
in inadequate pumping of blood around the body.
Hypertrophic cardiomyopathy (HCM) and dilated cardiomy-
opathy (DCM) are mainly caused by mutations in sarcomeric
proteins. HCM is characterised by left ventricular hypertrophy
(resulting from increased cell size or volume), increased sys-
tolic function and decreased diastolic function. At the histo-
logical level, hypertrophy and disarray of cardiomyocytes and
interstitial fibrosis is observed. DCM, on the other hand, is
characterised by ventricular dilation and contractile dysfunc-
tion of the left and/or right ventricles. Depending on the
location of the mutation, HCM or DCM is induced; in HCM
regions of sarcomeric proteins are mutated that are directly
involved in force transmission, whereas the regions that are
mutated in DCM are involved in force transmission from the
sarcomere to the cytoskeleton. The majority of mutations in
sarcomeric proteins are found in myosin heavy chain β and
myosin binding protein C [2, 3].
Besides mutations in proteins that affect force generation
and transmission, mutations in proteins at the Z-disc (and
also the M-band) that disrupt stress sensing and downstream
signalling have also been implicated in cardiomyopathies
and severe hypertrophic responses. For instance, calcineurin,
muscle-specific LIM protein (MLP), T-cap, calsarcin-1, cy-
pher and Enigma homologue protein (ENH) interact with α-
actinin at the Z-disc and have been associated with cardio-
myopathies [4]. The putative stress sensor MLP has been
shown to be an essential component of the T-cap and titin
complex, stabilising the interaction between these proteins,
which can then sense an increase in stretch, followed by
activation of downstream signals for the induction of hyper-
trophy [5]. The calcium-dependent phosphatase calcineurin
is a key regulator of hypertrophy. Activated calcineurin de-
phosphorylates nuclear factor of activated T-cells (NFAT),
which subsequently translocate to the nucleus to activate
genes that are associated with stress, such as atrial natriuretic
factor (ANF) and brain natriuretic peptide (BNP), and genes
that encode foetal isoforms of contractile proteins, such as β-
myosin heavy chain (β-MHC). Calcineurin transgenic (Tg)
mice, expressing a constitutively active form of the catalytic
subunit of calcineurin in the heart, show massive hypertro-
phy, disorganised cardiomyocytes, fibrosis and enlarged
nuclei.
Calsarcin, a novel target for calcineurin, binds to both
calcineurin and α-actinin. Overexpression of calsarcin-1,
both in vitro and in vivo, has protective effects on hypertro-
phy by interfering with calcineurin-NFAT signalling, while a
lack of calsarcin-1 sensitises the calcineurin pathway and
shows accelerated formation of cardiomyopathy in response
to pathological stimuli. Cypher (or Oracle/ZASP) is
expressed in heart and skeletal muscle during mouse and
zebrafish development and interacts with α-actinin and
calsarcin. Deletion of cypher in mice and zebrafish resulted
in disruption of the Z-disc structure leading to DCM.
However, in mice only deletion of the long isoform of cypher
led to development of late-onset DCM, whereas deletion of
the short isoform had no effect. More interestingly, muta-
tions in cypher that cause DCM have been identified in
humans. These results indicate cypher as an essential com-
ponent of the α-actinin-calcineurin-calsarcin complex in
order to maintain cardiac structure and function. ENH is
another PDZ-LIM protein, which interacts with α-actinin,
calsarcin and cypher. In ENH−/−mice expression of the short
cypher isoform and calsarcin is lost, which leads to disrup-
tion of the Z-disc and development of DCM. These data
show an essential role for the Z-disc in the development of
cardiomyopathies and targeting these components could re-
veal strategies for possible new therapies for the treatment of
these diseases.
Actin signalling and transcriptional regulation in cardiac
development and disease
The actin cytoskeleton in striated muscles is organised in
sarcomeres for generation of contractile force, as we have
previously discussed. Actin is also important in other cellular
processes, including cytokinesis, migration, regulation of
cell shape and gene expression during development and
disease. In recent years, it has become clear that regulators
of actin dynamics are crucial for the assembly and mainte-
nance of functional sarcomeres [6]. Polymerisation of mo-
nomeric globular actin (G-actin) in filamentous actin (F-
actin) is regulated by several actin-binding proteins. Rho
GTPases (RhoA, Rac and Cdc42) induce actin polymerisa-
tion via the Rho-associated kinase (ROCK)-LIM kinase-
cofilin pathway. RhoA is highly expressed in embryonic
hearts, down-regulated in adult hearts and re-expressed dur-
ing cardiac hypertrophy. Heart-specific overexpression of
RhoA leads to the development of a DCM phenotype,
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whereas inhibiting ROCK protects the heart after aorta con-
striction. In addition, actin signalling has an important role in
the regulation of transcriptional activity of various transcrip-
tion factors, such as serum response factor (SRF),
myocardin-related transcription factors (MRTFs) and MEF2.
SRF is a member of the MADS (MCM1, Agamous,
Deficiens, SRF) family of transcription factors, which share
a conserved motif of 57 amino acids mediating
homodimerisation, association with other factors and
DNA-binding activity. Homodimeric SRF binds to a palin-
dromic DNA sequence (CC(A/T)6GG), which is called the
CArG box. Several SRF-mouse models have shown that
SRF is essential for cardiac development, as well as
maintaining adult cardiomyocytes. SRF is responsible for
maintaining the sarcomeric integrity in cardiomyocytes and
disruption of its expression results in DCM in mice.
Therefore, it is not surprising to find several sarcomeric
genes, such as skeletal and cardiac actin, α-MHC and β-
MHC, myosin light chain (MLC)2a and 2v, myomesin,
troponin C, and titin, to be targets of SRF [7].
Myocardin, a co-activator of SRF, is essential for smooth
muscle differentiation and activates expression of smooth
muscle genes in promoters with two adjacent CArG boxes
by binding these as homodimers. Cardiac specific deletion
(using an α-MHC-Cre mouse line) of myocardin leads to
decreased expression of sarcomeric genes (α-cardiac actin,
MLC2v, and tropomyosin) and connexin 43 and desmin,
which results in disruption of the structural organisation of
the sarcomere and intercalated discs, respectively.
Furthermore, the hearts of α-MHC-Cre-myocardinf/f showed
left atrial enlargement, hypertrophy, interstitial fibrosis and a
decreased cardiac function (decreased ejection fraction).
Myocardin also has an essential function during pathophys-
iological events in the heart; it is upregulated in several
in vivo and in vitro models of hypertrophy, as well as in
human patient hearts with idiopathic DCM. The hypertro-
phic marker ANF is a direct target of myocardin and
overexpression of myocardin in cardiomyocytes in vitro
leads to a hypertrophic response, which can be abolished
by expression of a dominant negative isoform lacking the
transcriptional activation domain.
Myocyte enhancer factor-2 (MEF2) is another MADS-
box transcription factor. Four isoforms of MEF2 exist (A–
D), of which isoforms A, C and D have distinct functions in
the heart. Knock-out studies show that MEF2A is essential
for energy metabolism and sarcomeric organisation in adult
hearts, MEF2C is involved in cardiac morphogenesis, and
MEF2D is a mediator of stress-dependent pathological
remodelling of the adult heart. On the other hand,
overexpression of these factors induced (dilated) cardiomy-
opathy in mice.
Transcriptional activity of SRF is regulated by Striated
Muscle Activator of Rho Signalling (STARS). STARS binds
to actin and activates RhoA, which promotes actin polymer-
isation and depletion of the G-actin pool. Subsequently,
MRTFs translocate to the nucleus (via decreased binding to
G-actin binding domain) and activate gene expression by
acting as co-factor for SRF. SRF induces actin genes, in this
way providing a negative feedback loop. STARS has been
shown to be a direct target of MEF2 in different models of
hypertrophy [7]. Thus, the formation of actin bundles is not
only necessary for cell movement and polarisation, but also
leads to the induction of signal-transduction pathways im-
portant for cardiac development and hypertrophy.
CHAP, a sarcomeric protein, important for cardiac
development and disease
Recently, following whole genome-wide microarray analysis
of pluripotent human embryonic stem cell differentiating
towards functional cardiomyocytes, we identified a novel
gene, which we named Cytoskeletal Heart-enriched Actin-
associated Protein (CHAP) (also known Synaptopodin-2-
like (SYNPO2L)) and which is highly expressed in heart
and skeletal muscle [8]. CHAP displays a significant homol-
ogy to myopodin and synaptopodin (31 % and 30 %, respec-
tively), which are both actin-bundling proteins that bind to
α-actinin. Whereas synaptopodin is expressed in kidney and
forebrain, myopodin is predominantly expressed in skeletal
muscle and at lower levels in heart and smooth muscle cells.
Interestingly, myopodin is localised at the Z-disc of skeletal
muscle cells and cardiomyocytes, but can be translocated to
the nucleus in a differentiation- and stress-dependent manner
[9]. Phosphorylated synaptopodin and myopodin, mediated
by inhibition of calcineurin activity, resulted in stabilisation
of the actin cytoskeleton in kidney podocytes [10] and trans-
location from the Z-disc to the nucleus in cardiomyocytes
[11], respectively.
Based on the homology of CHAP with both myopodin and
synaptopodin, we decided to further explore the role of CHAP
in cardiomyocyte differentiation and more specifically in sar-
comere organisation and function. We identified two isoforms
of human and mouse CHAP: a long isoform CHAPa and a
shorter isoform CHAPb. CHAPa and CHAPb isoforms are
almost identical, containing a putative nuclear localisation
signal (NLS) and actin binding sites. The N-terminal of
CHAPa contains an additional PDZ domain. In chick one
CHAP isoform has been identified, which shows homology
with the human and mouse CHAPa gene [12]. During mouse
embryonic development, ChapB is first expressed at the car-
diac crescent stage (E7.75), later in the linear heart tube and in
the looped heart. From embryonic day 10 onward, expression
is also detected in somites (giving rise to skeletal muscle).
Expression ofChapB is downregulated in adult hearts, where-
as ChapA is expressed in adult heart and skeletal muscle [13].
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Furthermore, Chap is expressed in developing muscles, such
as jaw, tongue and eye muscle. A similar expression pattern of
CHAP in chick embryos was observed [12]. In addition, we
showed expression of mouse Chap in skeletal muscle and
smooth muscles of the aorta, carotid artery and coronary
arteries. These results suggest a function for CHAP in muscle
development and adult muscle.
Similar to myopodin, we demonstrated that CHAP was
localised at the Z-disc of cardiomyocytes and skeletal muscle
cells, supported by co-localisation of α-actinin and the lack of
overlap in localisation with the M-band marker myomesin
(Fig. 1).Moreover, besides their co-localisation, we also showed
that CHAP was able to interact with α-actinin-2. In a next step
we studied the role of CHAP during zebrafish development.
Morpholino-mediated knock down of chap in zebrafish resulted
in defects in heart looping, cardiac oedema and disturbed skel-
etal muscle development [13]. These data indicated an essential
role for CHAP in cardiac and skeletal muscle development.
In order to investigate the role of CHAP in adult mice, we
generated transgenic mice by heart-specific overexpression
of both isoforms of CHAP. CHAPb transgenic mice
displayed a phenotype, which resembles dilated cardiomy-
opathy and was associated with abnormal atrial conduction
(unpublished data). Interestingly, in a recent large-scale
meta-analysis of multiple genome-wide association studies
of European ancestry six new susceptibility loci for atrial
fibrillation were identified, of which one locus was located
5 kb upstream of SYNPO2L (CHAP) and 20 kb upstream of
MYOZ1 (calsarcin-2) [14]. These findings corroborate the
changed atrial conductivity in CHAP Tg mice.
Clinical perspective
It is evident that well-coordinated activities of the various
components of the sarcomere are necessary for proper func-
tion of the heart muscle. Changes in expression levels,
localisation or function of these components may ultimately
lead to heart failure. Heart failure patients with impaired
cardiac contractility can be treated with drugs that enhance
β-receptor cAMP-dependent protein kinase pathways, lead-
ing to increased phosphorylation of many different target
proteins (including sarcomeric proteins) and increased car-
diac contractility. However, detrimental side effects can be
observed, because of the lack of selectivity of these drugs.
Nevertheless, recent successful development of selective
activators of sarcomeric contractile and their regulatory pro-
teins (i.e. kinases) demonstrate that the sarcomere is a po-
tentially promising drug target [15].
In addition, significant recent advances in (human) plu-
ripotent stem cell biology now enable efficient generation of
functional cardiomyocytes in vitro from patients and healthy
individuals [16]. Studying abnormal cardiomyocyte function
at the cellular level may provide a better understanding of the
underlying mechanism(s) responsible for the cardiac disease
phenotype in patients. Moreover, implementation of in vitro
cardiac disease models for drug discovery may be valuable
for screening and identification of effective and selective
drugs, leading to improved therapeutic strategies.
In conclusion, the perception of the sarcomere has con-
siderably changed during the last two decades, going from a
static contractile unit, responsible for generation and propa-
gation of mechanical force, to a dynamic unit which, in
addition to its essential role in contractility, is important for
sensing mechanical stress or other changes in upstream sig-
nalling and the translation to adequate downstream signal-
ling events. An increased knowledge in sarcomeric biology
and function will be fundamental for unravelling signalling
pathways that are important for both muscle development
and disease. Moreover, recent advances in pharmacological
interventions with small molecule drugs have shown func-
tional responses at the level of individual myosin and actin
filaments, leading to an increased awareness of the potential
of sarcomeric proteins as pharmacological targets. Ultimately,
Fig. 1 CHAP is localised at the Z-disc. Mouse embryonic stem cells
were differentiated to cardiomyocytes and immunostained with anti-
bodies for the Z-disc protein CHAP (green, left), M-band marker
myomesin (red, middle). Nuclei are stained with TOPRO-3 (blue). In
the merge panel (right) it can be appreciated that CHAP and myomesin
do not co-localise
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this may lead to new therapeutic strategies for the treatment of
a variety of muscle diseases.
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